Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy ...

Vertex Resource Group Ltd. ("Vertex" or the "Company") reports its financial and operational results for the third quarter ...

Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Povetacicept is an investigational dual BAFF and APRIL inhibitor being tested for various glomerulonephritis types in clinical trials.

The beginning of story’s end airs Sunday. It’s the vertex. Where the worst nightmares of all psychological family dramas come ...

Intellia Therapeutics NTLA is currently advancing two late-stage in vivo pipeline candidates – nex-z (or, NTLA-2001) for ...

These data were presented today during a late-breaking session at the American Heart Association (AHA) Scientific Sessions and published simultaneously in The New England Journal of Medicine (NEJM) in ...

Adding an investigational nonsteroidal mineralocorticoid receptor antagonist (MRA) to an SGLT2 inhibitor led to a superior ...

The European venture firm raised 500 million euros, or about $579 million, for its latest fund, which follows a flurry of ...

In vivo preclinicalproof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports ...